Cancer Testing - Search News

FDA Panel Narrowly Backs Multi-Cancer Blood Test

FDA panel narrowly backs multi-cancer blood test despite doubts it works

A blood test that aims to catch more than 50 types of cancer before symptoms appear narrowly won the backing of U.S. Food and Drug Administration (FDA) advisers Wednesday, even as several doubted it works.

· 13h · on MSN

A controversial, cancer-detecting blood test just got backed by key FDA panel

· 9h

FDA-endorsed blood test can spot early signs of more than 50 types of cancer, drugmaker says

· 1d

FDA advisory panel endorses controversial cancer blood test

An advisory committee to the Food and Drug Administration recommended on Wednesday that the agency approve a blood test designed to detect various cancers in the early stages, despite concerns among d...

· 18h

FDA panel endorses blood cancer test from Grail

· 1d

Blood test for multiple cancers clears crucial hurdle on track to FDA approval

This Controversial Cancer Test Just Passed a Key FDA Vote. Here’s Why It’s Dividing Experts

Grail’s Galleri test costs $1,000 and promises comprehensive early-stage screening for more than 50 types of cancer.

Nature

Colorectal Cancer Detection and Screening Techniques articles from across Nature Portfolio

Current US FDA-cleared stool-based colorectal cancer (CRC) molecular screening tests include fecal immunochemical tests (FIT) for occult blood detection; however, integration with nucleic acid-based biomarkers requires separate workflows, thereby...

51m

Lord’s Mark moves AI-based breast cancer screening technology towards final trials

Technical Committee Approves Final Clinical Trial Stage; Company Targets Regulatory Clearances and Commercial Launch by April 2027.